Validity of fecal occult blood test in the National Cancer Screening Program, Korea

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Shin, Aesun ^a   Choi, Kui Son ^a   Jun, Jae Kwan ^a   Noh, Dai Keun ^a   Suh, Mina ^a   Jung, Kyu Won ^a   Kim, Byung Chang ^a   Oh, Jae Hwan ^a   Park, Eun Cheol ^b  

^a National Cancer Center   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SCREENING; COLORECTAL CANCER; DATA BASE; DIAGNOSTIC KIT; FEMALE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; OCCULT BLOOD TEST; PREDICTIVE VALUE; RECTUM CANCER; SENSITIVITY AND SPECIFICITY; VALIDITY;

AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; FECES; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PREDICTIVE VALUE OF TESTS; REPUBLIC OF KOREA;

EID: 84892600900     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079292     Document Type: Article

References (33)

1. Smith-Warner SA, Spiegelman D, Yaun SS, van den Brandt PA, Folsom AR, et al. (1998) Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 279: 535-540.
2. Jung KW, Shin HR, Kong HJ, Park S, Won YJ, et al. (2010) Long-term trends in cancer mortality in Korea (1983-2007): a joinpoint regression analysis. Asian Pac J Cancer Prev 11: 1451-1457.
3. Jung KW, Park S, Kong HJ, Won YJ, Lee JY, et al. (2011) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat 43: 1-11.
4. Jung KW, Park S, Kong HJ, Won YJ, Lee JY, et al. (2012) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat 44: 11-24.
5. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, et al. (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328: 1365-1371.
6. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, et al. (2000) The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 343: 1603-1607.
7. Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM (1992) Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 84: 1572-1575.
8. Selby JV, Friedman GD, Quesenberry CP, Jr., Weiss NS (1992) A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 326: 653-657.
9. Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW (2010) Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 60: 99-119.
10. Sung JJ, Lau JY, Young GP, Sano Y, Chiu HM, et al. (2008) Asia Pacific consensus recommendations for colorectal cancer screening. Gut 57: 1166-1176.
11. Yoo KY (2008) Cancer control activities in the Republic of Korea. Jpn J Clin Oncol 38: 327-333.
12. Castiglione G, Visioli CB, Ciatto S, Grazzini G, Bonanomi AG, et al. (2007) Sensitivity of latex agglutination faecal occult blood test in the Florence District population-based colorectal cancer screening programme. Br J Cancer 96: 1750-1754.
13. Ciatto S, Martinelli F, Castiglione G, Mantellini P, Rubeca T, et al. (2007) Association of FOBT-assessed faecal Hb content with colonic lesions detected in the Florence screening programme. Br J Cancer 96: 218-221.
14. Haug U, Knudsen AB, Brenner H, Kuntz KM (2011) Is fecal occult blood testing more sensitive for left- versus right-sided colorectal neoplasia? A systematic literature review. Expert Rev Mol Diagn 11: 605-616.
15. Won YJ, Sung J, Jung KW, Kong HJ, Park S, et al. (2009) Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat 41: 122-131.
16. (1992-4) International Statistical Classification of Diseases and Related Health Problems, Tenth Revision. Vols 1-3. Geneva, Swizerland: World Health Organization.
17. Rennert G, Rennert HS, Miron E, Peterburg Y (2001) Population colorectal cancer screening with fecal occult blood test. Cancer Epidemiol Biomarkers Prev 10: 1165-1168.
18. Allison JE (2005) Colon Cancer Screening Guidelines 2005: the fecal occult blood test option has become a better FIT. Gastroenterology 129: 745-748.
19. Dancourt V, Lejeune C, Lepage C, Gailliard MC, Meny B, et al. (2008) Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms. Eur J Cancer 44: 2254-2258.
20. Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsene D, et al. (2007) Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 56: 210-214.
21. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, et al. (2008) Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135: 82-90.
22. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R (2008) Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 149: 638-658.
23. Park DI, Ryu S, Kim YH, Lee SH, Lee CK, et al. (2010) Comparison of guaiacbased and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 105: 2017-2025.
24. Launoy GD, Bertrand HJ, Berchi C, Talbourdet VY, Guizard AV, et al. (2005) Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer 115: 493-496.
25. Hol L, Wilschut JA, van Ballegooijen M, van Vuuren AJ, van der Valk H, et al. (2009) Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 100: 1103-1110.
26. Park MJ, Choi KS, Lee YK, Jun JK, Lee HY (2012) A comparison of qualitative and quantitative fecal immunochemical tests in the Korean national colorectal cancer screening program. Scand J Gastroenterol 47: 461-466.
27. Malila N, Oivanen T, Malminiemi O, Hakama M (2008) Test, episode, and programme sensitivities of screening for colorectal cancer as a public health policy in Finland: experimental design. BMJ 337: a2261.
28. Brenner H, Haug U, Hundt S (2010) Inter-test agreement and quantitative cross-validation of immunochromatographical fecal occult blood tests. Int J Cancer 127: 1643-1649.
29. Parra-Blanco A, Gimeno-Garcia AZ, Quintero E, Nicolas D, Moreno SG, et al. (2010) Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. J Gastroenterol 45: 703-712.
30. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, et al. (2005) A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 129: 422-428.
31. Zhu MM, Xu XT, Nie F, Tong JL, Xiao SD, et al. (2010) Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: a meta-analysis. J Dig Dis 11: 148-160.
32. Choi KS, Lee HY, Jun JK, Shin A, Park EC (2012) Adherence to follow-up after a positive fecal occult blood test in an organized colorectal cancer screening program in Korea, 2004-2008. J Gastroenterol Hepatol 27: 1070-1077.
33. Steele RJ, McClements P, Watling C, Libby G, Weller D, et al. (2012) Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. Gut 61: 576-581.